Don’t Ignore The Fact That This Insider Just Sold Some Shares In GenMark Diagnostics, Inc. (NASDAQ:GNMK)

Investors may wish to note that the Senior VP of Operations of GenMark Diagnostics, Inc., Brian Mitchell, recently netted US$2.8k from selling stock, receiving an average price of US$6.55. However we note that the sale only shrunk their holding by 0.2%.

See our latest analysis for GenMark Diagnostics

GenMark Diagnostics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by the CEO, President & Director, Hany Massarany, for US$371k worth of shares, at about US$6.79 per share. So what is clear is that an insider saw fit to sell at around the current price of US$6.11. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it’s not too bad (but it’s still not a positive).

In the last twelve months insiders netted US$2.0m for 308k shares sold. In the last year GenMark Diagnostics insiders didn’t buy any company stock. The chart below shows insider transactions (by individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGM:GNMK Recent Insider Trading, August 25th 2019
NasdaqGM:GNMK Recent Insider Trading, August 25th 2019

Does GenMark Diagnostics Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 5.3% of GenMark Diagnostics shares, worth about US$18m. We’ve certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At GenMark Diagnostics Tell Us?

Insiders haven’t bought GenMark Diagnostics stock in the last three months, but there was some selling. And there weren’t any purchases to give us comfort, over the last year. Insider ownership isn’t particularly high, so this analysis makes us cautious about the company. We’d think twice before buying! Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for GenMark Diagnostics.

Of course GenMark Diagnostics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.